Corneal Neovascularization Clinical Trial
Official title:
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00555594 -
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
|
Phase 2/Phase 3 | |
Completed |
NCT00004430 -
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
|
N/A | |
Completed |
NCT00769145 -
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
|
Phase 1 | |
Completed |
NCT01257750 -
Treatment of Corneal Neovascularization With Topical Pazopanib
|
Phase 1/Phase 2 | |
Recruiting |
NCT04787471 -
Corneal Crosslinking for Treatment of Corneal Neovascularization
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
Active, not recruiting |
NCT00992849 -
Bevacizumab for the Treatment of Corneal Neovascularization
|
Phase 2 | |
Withdrawn |
NCT00515684 -
Corneal Thinning During Topical Bevacizumab Therapy
|
N/A | |
Terminated |
NCT02797704 -
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
Terminated |
NCT01868360 -
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
|
Phase 1 | |
Withdrawn |
NCT02042027 -
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
|
Phase 1 | |
Recruiting |
NCT04215393 -
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
|
Phase 1 | |
Completed |
NCT00797303 -
The Effect of Bevacizumab on Corneal Neovascularization
|
Phase 4 | |
Recruiting |
NCT05659940 -
Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
|
||
Completed |
NCT00559936 -
Topical Avastin for Treatment of Corneal Neovascularization
|
Phase 1 | |
Completed |
NCT01072357 -
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
Recruiting |
NCT04620109 -
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
|
Phase 1 | |
Recruiting |
NCT05011916 -
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
Completed |
NCT01996826 -
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
Terminated |
NCT00915590 -
Topical IL-1-Ra for Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 |